Our multi-disciplinary team is advancing a paradigm shift in medicine by pioneering a physics-driven approach to drug design.
Our drug design platform is purpose-built to design novel small molecule therapeutics capable of addressing biologically and genetically validated but previously intractable protein targets. Our lead program, a highly differentiated small molecule STING agonist, recently entered Phase I clinical trials for patients with advanced solid tumors or lymphoma.
We base our drug development process on a proprietary physics-driven platform comprised of our expertise in quantum mechanics, statistical thermodynamics, molecular simulations and super-computing infrastructure.
Our physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratory and clinical development capabilities. We have developed the most accurate force field in the industry to model both proteins and small molecules and are continuously developing new tools and applications to improve drug design.Physics-Driven Platform
We’re focused on biologically and genetically validated protein targets that have, until now, been considered “undruggable.” Our drug design process is built on three essential concepts: our multi-disciplinary team; integrated approach and deep physics insights; and our leadership in understanding conformational modulation.Drug Design
Members of our senior science team are the lead authors for some of the most innovative and frequently cited publications appearing in prestigious industry journals, with over 200 peer-reviewed articles and over 20,000 citations.Scientific Publications